Zaloguj Zarejestruj się zadarmo

Kazia Therapeutics organizacji Akcje w obiegu

Jaka jest wartość Akcje w obiegu organizacji Kazia Therapeutics?

Wartość Akcje w obiegu organizacji Kazia Therapeutics Limited to 116.518M 88.25%

Jaka jest definicja Akcje w obiegu?

Akcje w obiegu (Shares float) jest częścią akcji korporacji, które znajdują się w rękach inwestorów publicznych, a nie w postaci zablokowanych zapasów.

Shares float represents the portion of shares of a corporation that are in the hands of public investors as opposed to locked-in stock held by promoters, company officers, controlling-interest investors, or government. This number is sometimes seen as a better way of calculating market capitalization because it provides a more accurate reflection of what public investors consider the company to be worth. In this context, the float may refer to all the shares outstanding that can be publicly traded

The float is calculated by subtracting the locked-in shares from outstanding shares. Stocks with smaller floats tend to be more volatile than those with larger floats. In general, the large holdings of founding shareholders, corporate cross-holdings, and government holdings in partially privatized companies are excluded when calculating the size of a public float.

Akcje w obiegu firm w Health Care sektor na ASX w porównaniu do Kazia Therapeutics

Czym się zajmuję organizacja Kazia Therapeutics?

Kazia Therapeutics Limited, an oncology-focused biotechnology company, develops anti-cancer drugs. Its lead development candidate is GDC-0084, a small molecule, brain-penetrant inhibitor of the PI3K/Akt/mTor pathway, which is developed as a potential therapy for glioblastoma. The company is also developing Cantrixil, which is being developed for the treatment of ovarian cancer and is in hospitals across Australia and the United States under an Investigational New Drug application. Kazia Therapeutics Limited has collaboration agreements St Jude Childrens Hospital; Dana-Farber Cancer Institute; Alliance for Clinical Trials in Oncology; Memorial Sloan Kettering Cancer Centre; and University of Newcastle. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. Kazia Therapeutics Limited was founded in 1994 and is based in Sydney, Australia.

Firmy z akcje w obiegu podobne do Kazia Therapeutics